Libre Duo: How Can Glucose-Ketone Monitoring Help?

What does the FDA-authorized Libre Duo monitor measure?

The Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System samples fluid beneath the skin every minute and sends results to a compatible smartphone. Users can follow changes over time and receive alerts about elevated ketones. [FDA announcement](https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-wearable-device-continuously-monitors-both-ketone-levels-and-blood-sugar)

The prescription device is indicated for people with diabetes aged 2 years and older. Its authorized use includes informing treatment adjustments, but ketone results must be interpreted alongside glucose, symptoms, eating patterns and exercise. The FDA classification order also identifies inaccurate readings, misunderstood results and interrupted data transmission as potential sources of treatment errors. These limitations make training and an individualized response plan essential parts of implementation. [FDA classification order](https://www.accessdata.fda.gov/cdrh_docs/pdf25/DEN250049.pdf)

Why can ketone monitoring matter when glucose is not very high?

Diabetic ketoacidosis, or DKA, develops when insufficient insulin allows excessive ketone production and harmful acid accumulation. Illness, missed insulin and interrupted pump delivery can trigger it. Although most common in type 1 diabetes, DKA also occurs in type 2 diabetes. Continuous ketone information could help reveal an emerging problem between individual tests; that potential benefit still depends on recognizing the pattern and taking appropriate action. [CDC explanation of DKA](https://www.cdc.gov/diabetes/about/diabetic-ketoacidosis.html)

A consensus report convened by major diabetes organizations explains that DKA can occur with relatively modest glucose levels, including in association with SGLT2 inhibitor medicines. It recommends direct blood measurement of beta-hydroxybutyrate when diagnosing and monitoring DKA. A wearable measures a different fluid compartment and does not assess blood acidity, so its readings cannot establish the diagnosis by themselves. Suspected DKA requires clinical assessment and appropriate laboratory testing. [Hyperglycemic crises consensus report](https://doi.org/10.2337/dci24-0032)

What does the evidence show about preventing diabetes emergencies?

The FDA reviewed six clinical studies involving more than 600 participants. Its announcement reports that the device tracked meaningful ketone changes throughout its wear period, including elevations before DKA developed. It does not report a comparative reduction in hospital admissions or deaths. [FDA evidence summary](https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-wearable-device-continuously-monitors-both-ketone-levels-and-blood-sugar)

That distinction matters: detecting a warning signal and preventing an emergency are separate outcomes. Future comparative research could clarify whether alerts lead to earlier treatment, fewer admissions and acceptable workloads for families and clinicians. Access, reliable supplies and the ability to act on readings will also influence the technology's practical value.

Patients still need instructions for illness, insulin adjustments and urgent help. Vomiting that prevents fluid intake, breathing difficulty or multiple DKA symptoms warrant immediate emergency assessment rather than waiting for another sensor reading. Established DKA requires urgent treatment, commonly including insulin, fluids and electrolyte replacement. [CDC emergency guidance](https://www.cdc.gov/diabetes/about/diabetic-ketoacidosis.html)